Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Complicated intra-abdominal infections Age: Adult |
Dose: Intravenous – 500 mg Frequency: every 8 hours infused over 1 hour Duration: 5-14 days Note: May switch to an appropriate oral therapy, after at least 3 days of parenteral therapy upon evidence of clinical improvement. |
|
Indication: Complicated urinary tract infections; Pyelonephritis Age: Adult |
Dose: Intravenous – 500 mg Frequency: every 8 hours infused over 1 hour Duration: 10 days Note: May switch to an appropriate oral therapy, after at least 3 days of parenteral therapy upon evidence of clinical improvement. Duration can be extended up to 14 days for patients with concurrent bacteraemia. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: less than 18 years |
Dose: Not established Note: Safety and efficacy not established |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment: Creatinine Clearance 30-50 ml/min |
Dose: Intravenous infusion – 250 mg Frequency: every 8 hours Duration: over 1 hour |
|
Condition: Renal impairment: Creatinine Clearance 11-29 ml/min |
Dose: Intravenous infusion – 250 mg Frequency: every 12 hours Duration: over 1 hour |
Administration
- Hospital use only
- Given via IV infusion
Side Effect
- Headache (4-16%)
- Nausea (4-12%)
- Diarrhea (6-11%)
- Anemia (2-10%)
- Phlebitis (4-8%)
- Rash (1-5%)
- Pruritus (3%)
- Transaminases elevated (1-2%)
- Oral candidiasis (1%)
- Renal impairment/failure (1%)
- Anaphylaxis
- toxic epidermal necrolysis
- Stevens-Johnson Syndrome
- interstitial pneumonia
- seizure
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Probenecid
|
Increased plasma concentration
|
|
Valproic acid
|
May decrease plasma levels, increasing risk of seizures
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Not available
|
Not available
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Reconstituted suspension may be held for 1 hr prior to dilution in infusion bag. Following dilution of the suspension with NaCl 0.9%, stability is 8 hr at room temperature or 24 hr between 2-8°C. Stability of solution when diluted with dextrose 5% injection is 4 hr at room temperature or 24 hr between 2-8°C.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.